Events Calendar

May 29-June 2

American Society of Clinical Oncology

Virtual

Poster Presentations:
Ph 2 trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma

Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy

December 3-5, 2019

Oncolytic Virotherapy Summit

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Pharmico-Dynamic Non-Invasive Monitoring Techniques”

October 28-31, 2019

World Vaccine Congress Europe 2019

Barcelona, Spain

Shruthi Naik, Ph.D., Vyriad Vice President of Comparative Oncology
Presentation: “Unlocking the Potential of Oncolytic Viruses to Target Cancer Cells”

October 9-12, 2019

International Oncolytic Virus 12th Annual Conference

Rochester, MN

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Opening Remarks
Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Inflaming tumors with systemic VSV therapy”

August 8, 2019

Cambridge Healthtech Institutes (CHI) 2nd Annual Immuno-Oncology Investing & Partnering Forum

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Novel Therapeutics and Diagnostics for Cancer Immunotherapy”

August 6-7, 2019

Cambridge Health Institute’s (CHI) 4th Annual Oncolytic Virus Immunotherapy Summit

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic OV Therapy Using Voyager-V1”

July 21-23, 2019

The 25th Annual Meeting of Japan Society of Gene and Cell Therapy and The International Gene & Cell Therapy Symposium

Tokyo, Japan

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: "Intravenous Virotherapy: Inflaming Tumors via the Blood Stream"

April 10-11, 2019

Cambridge Healthtech Institute’s Inaugural Oncolytic Viral Therapy Conference: Engineering, Translational and Clinical Strategies

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Antibody Targeted Viruses: The Next Generation of Oncolytics”

March 18-22, 2019

Immuno-Oncology Summit Europe

London, UK

March 11-13, 2019

Cambridge Healthtech Institute’s 4th Annual Cancer Immunotherapy: Executive Summit

San Francisco, CA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Voyager-V1: Systemic, Single-cycle, Trackable Oncolytic Virotherapy”

February 11-12, 2019

Bio CEO and Investor Conference

New York, NY

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Presentation: “Oncolytic Viruses for IV Cancer Therapy"

January 7-10, 2019

37th Annual JP Morgan Healthcare Conference

San Francisco, CA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 37th Annual JP Morgan Healthcare Conference in San Francisco.

December 4-6, 2018

4th Oncolytic Virotherapy Summit

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus.”
Dr. Russell will also co-chair a panel session entitled: Comparing and Contrasting Virus Types.

November 27-29, 2018

30th Annual Piper Jaffray Healthcare Conference

New York, NY

Stephen J. Russell, M.D., Ph.D., Vyriad President and CEO, attended the 30th Annual Piper Jaffray Healthcare Conference in New York.

August 27-28, 2018

Cambridge Healthtech Institute’s 3rd Annual Oncolytic Virus Immunotherapy: Commercializing the Exciting Potential of Oncolytic Virotherapy

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Progress with Oncolytic Vesicular Stomatitis Viruses”

June 26-28, 2018

Armed Oncolytic Immunotherapies Summit

Frankfurt, Germany

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform”
Dr. Russell will participate in a panel discussion, "Explore Novel Approaches to Identify the Most Rational Combinations“

June 1-5, 2018

American Society of Clinical Oncology (ASCO) Annual Meeting

Chicago, Illinois

Alice Bexon, M.D., Vyriad Chief Medical Officer will attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

May 16-19, 2018

18th Annual American Society of Cell & Gene Therapy (ASGCT) meeting

Chicago, IL

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been elected Vice-President of ASGCT. ASGCT has elected four new members to the Board of Directors, including Dr. Stephen J. Russell as new incoming vice president. Dr. Russell will serve a yearlong term as vice president before serving as ASGCT's president-elect and, finally, president through the 2021 annual meeting. Dr. Russell will be Co-Chairing: Clinical Trials Spotlight I at the annual meeting. Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to present: Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging and Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging

April 9-12, 2018

International Oncolytic Virus Conference

Oxford, UK

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to Chair, Innate and collateral adaptive tumor immunity. Dr. Russell will also participate in Steve Russell (Once should be enough!) vs. Alan Melcher (Repeat dosing is crucial!) Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to Chair, Translation, imaging and clinical breakthroughs. Dr. Peng will be presenting: Oncolytic virus encoding IFNbeta: optimizing therapeutic index.

January 8-11, 2018

36th Annual JP Morgan Healthcare Conference

San Francisco, CA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 36th Annual JP Morgan Healthcare Conference in San Francisco.

December 5-7, 2017

Oncolytic Virotherapy Summit

Miami, Florida

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, was invited as a panel member for: How Can We Improve the Efficacy of Oncolytic Virotherapies? Dr. Russell also provided a presentation entitled “VSV-IFNb-NIS and MV-NIS: A Tale of Two Paradigms” and managed a workshop entitled “Optimizing Oncolytic Viruses: Identifying the Right Viral Platform”

November 28-29, 2017

28th Annual Piper Jaffray Healthcare Conference

New York, New York

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presented “Oncolytic Virotherapy: The Next Major Breakthrough in Cancer Treatment” at the 28th Annual Piper Jaffray Healthcare Conference

November 8-12, 2017

The 32nd Annual Society for Immunotherapy of Cancer (SITC) meeting

National Harbor, Maryland

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, attended the annual SITC meeting

November 4, 2017

Dr. Boenjamin Setiawan Distinguished Lectureship for 2017

Jakarta, Indonesia

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Invited to present “Oncolytic Viruses: An Emerging Cornerstone for Immuno-oncology” at the Dr. Boenjamin Setiawan Distinguished Lecture Series

February 23-25, 2017

ASCO-SITC Clinical Immuno-Oncology Symposium

Orlando, Florida

Stephen J Russell from Vyriad was invited to present on "Viral Therapy" at the ASCO-SITC conference on exploiting viruses for cancer therapy in combination with immune modulators.

October 1-4, 2016

The 10th International Meeting on Replicating Oncolytic Virus Therapeutics

Vancouver, Canada

Kah-Whye Peng, PhD, CTO of Vyriad gave a Plenary presentation entitled “Vesicular stomatitis virus (VSV) as an oncolytic agent”. Stephen J. Russell, MD, PhD, CEO & President of Vyriad gave a Plenary presentation entitled “Measles as a versatile oncolytic agent”.

June 18, 2016

35th Annual Meeting of the American Society of Virology

Blacksburg, VA

Keynote Lecture: “Oncolytic Viruses: Past, Present, and Future” Stephen J. Russell, MD, PhD, CEO & President, Vyriad.